Fondaparinux indications: Difference between revisions

Revision as of 19:05, 14 February 2009

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Fondaparinux sodium (Arixtra) Injection is indicated for the prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism:

in patients undergoing hip fracture surgery, including extended prophylaxis;
in patients undergoing hip replacement surgery;
in patients undergoing knee replacement surgery;
in patients undergoing abdominal surgery who are at risk for thromboembolic complications.

Fondaparinux sodium (Arixtra) Injection is indicated for:

the treatment of acute deep vein thrombosis when administered in conjunction with warfarin sodium, and
the treatment of acute pulmonary embolism when administered in conjunction with warfarin sodium when initial therapy is administered in the hospital.

Adapted from the FDA Package Insert.

@@ Line 1: / Line 1: @@
 {{CMG}}
+==Indications==
 '''Fondaparinux sodium''' (Arixtra) Injection is indicated for the prophylaxis of deep vein thrombosis, which may lead to [[pulmonary embolism]]:
@@ Line 11: / Line 13: @@
 Fondaparinux sodium (Arixtra) Injection is indicated for:
-* the treatment of acute [[deep vein thrombosis]] when administered in conjunction with warfarin sodium, and
+* the treatment of acute [[deep vein thrombosis]] when administered in conjunction with [[warfarin sodium]], and
-* the treatment of acute [[pulmonary embolism]] when administered in conjunction with warfarin sodium when initial therapy is administered in the hospital.
+* the treatment of acute [[pulmonary embolism]] when administered in conjunction with [[warfarin sodium]] when initial therapy is administered in the hospital.